UB Paderborn / Katalog / Suche / in CDI

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12

Journal of clinical oncology, 2014-11, Vol.32 (31), p.3490-3496

2014

Volltextzugriff (PDF)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients

Current oncology (Toronto), 2022-10, Vol.29 (10), p.7953-7963

2022

Volltextzugriff (PDF)

A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma

BMC cancer, 2022-07, Vol.22 (1), p.720-720, Article 720

2022

Volltextzugriff (PDF)

Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review

Cancer treatment reviews, 2020-07, Vol.87, p.102032-102032, Article 102032

2020

Volltextzugriff (PDF)

Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events

Current oncology (Toronto), 2020-12, Vol.28 (1), p.52-59

2020

Volltextzugriff (PDF)

The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population

Journal of geriatric oncology, 2019-05, Vol.10 (3), p.411-414

2019

Volltextzugriff (PDF)

Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors

Melanoma research, 2021-06, Vol.31 (3), p.258

2021

Volltextzugriff (PDF)

Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review

Surgical oncology, 2024-06, Vol.54, p.102077, Article 102077

2024

Volltextzugriff (PDF)

[18F]‐FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study

Cancer, 2017-08, Vol.123 (15), p.2860-2866

2017

Volltextzugriff (PDF)

Discordance Between Conclusions Stated in the Abstract and Conclusions in the Article: Analysis of Published Randomized Controlled Trials of Systemic Therapy in Lung Cancer

Journal of clinical oncology, 2012-10, Vol.30 (28), p.3552-3557

2012

Volltextzugriff (PDF)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma

Melanoma management, 2022-03, Vol.9 (1), p.MMT60-MMT60

2022

Volltextzugriff (PDF)

Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma

Current oncology (Toronto), 2022-03, Vol.29 (3), p.1501-1513

2022

Volltextzugriff (PDF)

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

Blood, 2015-08, Vol.126 (6), p.733-738

2015

Volltextzugriff (PDF)

Identification of genetic subtypes in follicular lymphoma

Blood cancer journal (New York), 2024-08, Vol.14 (1), p.128-13, Article 128

2024

Volltextzugriff (PDF)

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study

Leukemia & lymphoma, 2017-02, Vol.58 (2), p.372-381

2017

Volltextzugriff (PDF)

MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2903-2911

2013

Volltextzugriff (PDF)

Population survival impact of new targeted and immune based therapies for metastatic or unresectable melanoma

International journal of population data science, 2018-08, Vol.3 (4)

2018

Volltextzugriff (PDF)

Characteristics and outcomes of patients (pts) who developed immune-related adverse events (irAEs) with an initial presentation in the emergency department (ED)

Journal of clinical oncology, 2020-10, Vol.38 (29_suppl), p.201-201

2020

Volltextzugriff (PDF)

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Blood, 2014-12, Vol.124 (21), p.1712-1712

2014

Volltextzugriff (PDF)

Association of circadian timing of initial infusions of immune checkpoint inhibitors with survival in advanced melanoma

Immunotherapy, 2023-08, Vol.15 (11), p.819-826

2023

Volltextzugriff (PDF)

Severe Refractory Checkpoint Inhibitor‐Related Hepatitis Reversed With Anti‐Thymocyte Globulin and n‐Acetylcysteine

Hepatology (Baltimore, Md.), 2020-12, Vol.72 (6), p.2235-2238

2020

Volltextzugriff (PDF)

Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome

Canadian journal of cardiology, 2009-06, Vol.25 (6), p.e210-e212

2009

Volltextzugriff (PDF)

Long-term toxicities with immune checkpoint inhibitor (ICI) in melanoma patients

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21549-e21549

2022

Volltextzugriff (PDF)

Non-classical BRAF melanoma: A retrospective review of disease characteristics and prognostic implications

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e21060-e21060

2017

Volltextzugriff (PDF)

Can high-dose methotrexate be safely administered to outpatients?

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.34-34

2021

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients

A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma

Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review

Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events

The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population

Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors

Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review

[18F]‐FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study

Discordance Between Conclusions Stated in the Abstract and Conclusions in the Article: Analysis of Published Randomized Controlled Trials of Systemic Therapy in Lung Cancer

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma

Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

Identification of genetic subtypes in follicular lymphoma

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study

MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma

Population survival impact of new targeted and immune based therapies for metastatic or unresectable melanoma

Characteristics and outcomes of patients (pts) who developed immune-related adverse events (irAEs) with an initial presentation in the emergency department (ED)

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Association of circadian timing of initial infusions of immune checkpoint inhibitors with survival in advanced melanoma

Severe Refractory Checkpoint Inhibitor‐Related Hepatitis Reversed With Anti‐Thymocyte Globulin and n‐Acetylcysteine

Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome

Long-term toxicities with immune checkpoint inhibitor (ICI) in melanoma patients

Non-classical BRAF melanoma: A retrospective review of disease characteristics and prognostic implications

Can high-dose methotrexate be safely administered to outpatients?

Suchergebnisse filtern